妇科恶性肿瘤紫杉类药物临床应用专家共识

2019-09-15 中华医学会妇科肿瘤学分会 现代妇产科进展.2019,28(10):5-11.

妇科恶性肿瘤主要包括子宫颈癌、子宫内膜癌和卵巢癌等,化学治疗(以下简称“化疗冶)是其主要的辅助治疗措施,其中以铂类为基础的联合化疗,尤其是联合紫杉类药物,是妇科恶性肿瘤的基本化疗方案。紫杉类药物分为紫杉醇(溶剂型紫杉醇、紫杉醇脂质体和紫杉醇白蛋白结合型)和多烯紫杉醇(多西他赛)两类。在妇科恶性肿瘤治疗方面,国内外缺乏紫杉类药物临床应用专家共识,为使临床医师合理应用紫杉类药物,规范诊疗行为,中华医学

中文标题:

妇科恶性肿瘤紫杉类药物临床应用专家共识

发布日期:

2019-09-15

简要介绍:

妇科恶性肿瘤主要包括子宫颈癌、子宫内膜癌和卵巢癌等,化学治疗(以下简称“化疗冶)是其主要的辅助治疗措施,其中以铂类为基础的联合化疗,尤其是联合紫杉类药物,是妇科恶性肿瘤的基本化疗方案。紫杉类药物分为紫杉醇(溶剂型紫杉醇、紫杉醇脂质体和紫杉醇白蛋白结合型)和多烯紫杉醇(多西他赛)两类。在妇科恶性肿瘤治疗方面,国内外缺乏紫杉类药物临床应用专家共识,为使临床医师合理应用紫杉类药物,规范诊疗行为,中华医学会妇科肿瘤学分会组织专家讨论并形成共识。

 

拓展指南:妇科相关指南:

下载附件:

(因为版权问题,不支持下载)

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1079828, encodeId=913610e982843, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>特别棒!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f12852832, createdName=1209273456, createdTime=Tue Dec 14 09:11:50 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954665, encodeId=d7cb95466551, content=资料好好,但无法分享,遗憾!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:28:14 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882194, encodeId=8a50882194df, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de235309437, createdName=14883e84m10暂无昵称, createdTime=Wed Sep 02 15:06:24 CST 2020, time=2020-09-02, status=1, ipAttribution=)]
    2021-12-14 1209273456

    #肿瘤#特别棒!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1079828, encodeId=913610e982843, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>特别棒!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f12852832, createdName=1209273456, createdTime=Tue Dec 14 09:11:50 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954665, encodeId=d7cb95466551, content=资料好好,但无法分享,遗憾!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:28:14 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882194, encodeId=8a50882194df, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de235309437, createdName=14883e84m10暂无昵称, createdTime=Wed Sep 02 15:06:24 CST 2020, time=2020-09-02, status=1, ipAttribution=)]
    2021-04-07 ms6000001015893838

    资料好好,但无法分享,遗憾!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1079828, encodeId=913610e982843, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>特别棒!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f12852832, createdName=1209273456, createdTime=Tue Dec 14 09:11:50 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954665, encodeId=d7cb95466551, content=资料好好,但无法分享,遗憾!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 14:28:14 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882194, encodeId=8a50882194df, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de235309437, createdName=14883e84m10暂无昵称, createdTime=Wed Sep 02 15:06:24 CST 2020, time=2020-09-02, status=1, ipAttribution=)]
    2020-09-02 14883e84m10暂无昵称

    学习

    0